AL
ALVO.US Alvotech
- Market cap
- USD 1.52B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALVO.US undervalued?
Graham numberThe Graham number of Alvotech cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alvotech fundamental analysis
No fundamental analysis for Alvotech yet.
Alvotech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis…
Full company profileAlvotech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alvotech annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 31.9M | 66.6M | 36.8M | 83.0M | 91.4M | 490M | 586M | 431M |
| Gross Profit | 31.9M | 66.6M | 36.8M | 18.9M | -69.4M | 304M | 351M | 231M |
| Operating Income | -61.4M | -138M | -235M | -346M | -355M | 69.6M | 78.2M | 13.9M |
| EBITDA | -99.0M | -178M | -18.0M | -440M | -494M | -32.3M | 323M | 99.4M |
| Net Income | -210M | -170M | -102M | -514M | -552M | -232M | 27.9M | -188M |
| EPS | -0.86 | -5.44 | -3.25 | -2.60 | -2.43 | -0.87 | 0.10 | -0.57 |
| Balance Sheet | ||||||||
| Total Assets | - | 474M | 598M | 828M | 950M | 1.22B | 1.49B | 1.62B |
| Total Liabilities | - | 1.34B | 734M | 1.39B | 1.88B | 1.63B | 1.77B | 1.88B |
| Shareholders' Equity | - | -867M | -136M | -564M | -932M | -413M | -284M | -267M |
| Cash & Short-term Investments | - | 31.7M | 17.6M | 66.4M | 11.2M | 51.4M | 172M | 61.5M |
| Total Debt | - | 677M | 523M | 805M | 1.08B | 1.19B | 1.45B | 1.56B |
| Cash Flow | ||||||||
| Operating Cash Flow | -88.5M | -74.3M | -228M | -312M | -312M | -237M | -50.2M | -274M |
| Capital Expenditure | 8.05M | 12.0M | 40.6M | 49.0M | 46.5M | 57.0M | 64.5M | 106M |
| Free Cash Flow | -96.6M | -86.3M | -269M | -361M | -359M | -294M | -115M | -380M |
| Ratios | ||||||||
| ROA | - | -35.8% | -17.0% | -62.0% | -58.1% | -19.0% | 1.9% | -11.6% |
| Net Profit Margin | -657.5% | -255.3% | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% | -43.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alvotech dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 185M | 0.93 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alvotech
- Insiders 59.68%
- Institutions 12.85%
- Public & others 27.47%
- Shares outstanding 357M
- Free float 141M
Top funds holding ALVO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Total Intl Stock Index Inv | 2.59M | 0.73% | +55.19% | Sep 2026 |
| Vanguard Emerging Mkts Stock Idx Inv | 2.06M | 0.58% | +28.20% | Sep 2026 |
| iShares Biotechnology ETF | 1.35M | 0.38% | -0.19% | Oct 2026 |
| Stefnir Icelandic Growth | 792K | 0.22% | -10.78% | Sep 2026 |
| L&G Frontier Markets Eq Z USD Acc | 735K | 0.21% | +12.25% | Sep 2026 |
| Eaton Vance Glbl Macro Abs Ret Advtg I | 593K | 0.17% | 0.00% | Jul 2026 |
| Vanguard FTSE All-Wld ex-US ETF | 421K | 0.12% | +52.46% | Sep 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 326K | 0.09% | 0.00% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 289K | 0.08% | +0.20% | Oct 2026 |
| Schwab Emerging Markets Equity ETF™ | 182K | 0.05% | 0.00% | Oct 2026 |
| Vanguard Total World Stock ETF | 163K | 0.05% | +30.66% | Sep 2026 |
| Eaton Vance Glbl Macr Absolute Return I | 160K | 0.04% | 0.00% | Jul 2026 |
| Fidelity Nasdaq Composite ETF | 133K | 0.04% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® EM Sm Cp ETF | 102K | 0.03% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 102K | 0.03% | -46.99% | Aug 2026 |
| PUTM ACS Sustainable Idx EM Eq D £ Acc | 87.8K | 0.02% | +127.22% | Sep 2026 |
| Vanguard FTSE All-World UCITS ETF | 77.0K | 0.02% | 0.00% | Sep 2026 |
| Vanguard FTSE Emerg Markets ETF $Dis | 75.6K | 0.02% | +45.41% | Sep 2026 |
| Parametric Emerging Markets I | 66.7K | 0.02% | 0.00% | Jul 2026 |
| Eurizon Equity EmMkts New Frntrs Z Acc | 61.4K | 0.02% | 0.00% | Aug 2026 |
Alvotech company profile
- Company name
- Alvotech
- Ticker
- ALVO.US
- ISIN
- LU2458332611
- Exchange
- USA Stocks
- Listed since
- Jun 16, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,279
- Fiscal year end
- December
- Address
- 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
- Phone
- 354 422 4500
- Website
- alvotech.com
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Alvotech management
10- Mr. Vilhelm Robert WessmanFounder & Executive Chairman · born 1969
- Ms. Lisa GraverChief Executive Officer · born 1972
- Ms. Linda JonsdottirChief Financial Officer · born 1978
- Mr. Joseph E. McClellanChief Operating Officer · born 1974
- Ms. Neha PatelChief Information Officer
- Mr. Benedikt StefanssonVice President of Investor Relations & Global Communications
- Ms. Sarah MacleodHead of Global Communications
- Ms. Kathryn GunnarssonSenior Vice President of Global Talent & People Experience
- Mr. Anthony M. Maffia IIIChief Quality & Regulatory Officer
- Dr. Balaji Venkataramanan Prasad M.D.Chief Strategy Officer